Seer, Inc. Stock Price, News & Analysis

Seer (Nasdaq: SEER) reported third-quarter 2025 results for the period ended September 30, 2025. Revenue was $4.1 million, up 2% year-over-year, with product revenue $2.8 million and service revenue $1.2 million (including $300k related-party). Gross profit was $2.1 million and gross margin 51%. Operating expenses were $21.5 million; net loss was $18.2 million. Cash, cash equivalents and investments totaled approximately $251.2 million as of September 30, 2025. Seer reiterated full-year 2025 revenue guidance of $17–$18 million (midpoint +24% vs. 2024). The company noted nearly three times more instrument shipments year-to-date vs. 2024 and a record >60 third-party publications.

A webcast and conference call are scheduled for November 6, 2025 at 1:30 PM PT.

Seer (Nasdaq: SEER) announced that company management will participate in two investor conferences in November 2025: the UBS Global Healthcare Conference in Palm Beach Gardens, FL with 1x1 meetings on Wednesday, November 12, 2025, and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York with a fireside chat on Thursday, November 20, 2025 at 4:00 p.m. ET. Live webcasts will be available on the company's investor site investor.seer.bio, and archived replays will be posted on the company website after each conference.

Seer (Nasdaq: SEER) will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will stream on the Investor section of the company website at investor.seer.bio, and an archived replay will be posted on the website after the event.

Seer (Nasdaq: SEER) will present at the American Society of Human Genetics (ASHG) Annual Meeting, October 14-18, 2025 in Boston, highlighting how proteomics complements genomics to advance precision medicine.

Seer will host a featured CoLab session on October 16, 2025, 2:30-3:00 p.m. ET showcasing Proteograph-enabled multi-omic studies, including xenotransplantation immune profiling and isoform-specific biomarkers in idiopathic pulmonary fibrosis. Multiple independent research groups will also present Proteograph-generated findings on October 16 across poster and session formats, illustrating adoption of Seer’s Proteograph Product Suite for proteogenomic discovery and biomarker identification.

Seer (Nasdaq: SEER), a pioneer in proteomic insights, has appointed Isaac Ro to its Board of Directors. Ro brings significant financial leadership experience and deep sector expertise in life science tools and diagnostics. Currently a Partner at Catalio Capital Management, Ro has an impressive track record including serving as Executive Chairman of Haystack Oncology (acquired by Quest Diagnostics), CFO of Sema4 during its public listing, and CFO of Thrive Earlier Detection (acquired by Exact Sciences).

Prior to these roles, Ro led U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs from 2010 to 2019. He currently serves on the boards of PinkDx and PrognomiQ, bringing valuable experience to support Seer's growth and platform development initiatives.

Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 9th at 12:20 PM ET.

Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio. An archived version of the presentation will be made available after the conference.

Seer (Nasdaq: SEER), a life sciences company focused on proteomics, reported its Q2 2025 financial results with revenue of $4.1 million, representing a 32% year-over-year growth. The quarter was marked by the launch of their new high-throughput Proteograph ONE assay and SP200 automation instrument.

Key financial metrics include gross profit of $2.1 million with a 52% gross margin. Operating expenses decreased 21% to $22.6 million, while net loss improved to $19.4 million. The company maintains a strong balance sheet with $263.3 million in cash and investments. Seer reiterated its full-year 2025 revenue guidance of $17-18 million, projecting 24% growth at the midpoint.

Notable developments include a collaboration with Korea University for a 20,000-sample population-scale proteomics study focused on cancer diagnostics in young adults.

Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will engage in a fireside chat on August 13th at 9:00 a.m. ET.

Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio, with an archived replay available after the event.

Seer (Nasdaq: SEER), a company specializing in proteomic insights, has scheduled its Q2 2025 financial results announcement for August 6, 2025. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day.

Investors can access the live webcast through the Investor section at investor.seer.bio, where an archived replay will also be available after the event.